Advertisement

Topics

Iovance Biotherapeutics Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock

15:26 EDT 12 Oct 2018 | Investing News Network

Iovance Biotherapeutics (Nasdaq:IOVA) a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at a public offering price of $9.97 per share. As quoted in the press release: Iovance intends to use the proceeds from this offering … Continued

The post Iovance Biotherapeutics Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock appeared first on Investing News Network.

Original Article: Iovance Biotherapeutics Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock

NEXT ARTICLE

More From BioPortfolio on "Iovance Biotherapeutics Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...